Clinical Trials

MainTitle

Micronutrients and Antioxidants in HIV Infection (MAINTAIN)

This study is ongoing, but not recruiting participants.
Sponsor
Ottawa Hospital Research Institute

Collaborator
CIHR Canadian HIV Trials Network
Ontario HIV Treatment Network

Information provided by (Responsible Party)
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier
NCT00798772

First received: November 25, 2008
Last updated: April 3, 2017
Last Verified: April 2016
History of Changes
Purpose

Purpose

Infection with human immunodeficiency virus (HIV) causes decline in immunity or the ability to fight infection and progresses to acquired immunodeficiency disease (AIDS). Anti-HIV drug treatment has improved the prognosis of persons with HIV infection, but is expensive and potentially toxic. Low micronutrient levels occur in the blood even in early stages of HIV infection and increase risk of a poorer prognosis, but the role of micronutrient and antioxidant supplements in medical management of HIV/AIDS is not well defined. The proposed clinical trial aims to assess if supplementation of untreated HIV-infected adults with a micronutrient and antioxidant preparation can delay decline in immunity or disease progression or start of anti-HIV drug treatment compared with supplementation with standard multivitamins. If the findings are positive, the study has implications for health and health care savings.

Condition Intervention
HIV Infection

Dietary Supplement : Micronutrients and antioxidants
Dietary Supplement : Multivitamins and minerals

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Treatment group (Group A): Will receive micronutrients and antioxidants. Control group (Group B): Will receive identical appearing RDA multivitamins and minerals
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Control Clinical Trial Of Micronutrient & Antioxidant Supplementation in Persons With Untreated HIV Infection

Further study details as provided by Ottawa Hospital Research Institute:

Primary Outcome Measures

  • Time from baseline to CD4+ cell count <350 cells/mm3 (confirmed by two measures at least one week apart), or emergence of documented CDC-defined AIDS-defining illness, or start of ART [ Time Frame: Quarterly ]
Secondary Outcome Measures:
  • Non-AIDS related adverse events [ Time Frame: Quarterly ]
  • Tolerance of and adherence to study medication [ Time Frame: Quarterly ]
  • Time from baseline to CD4+ cell count <350 cells/mm3 (confirmed by two measures at least one week apart) [ Time Frame: Quarterly ]
  • Time from baseline to emergence of documented CDC-defined AIDS-defining illness [ Time Frame: Quarterly ]
  • Time from baseline to start of ART [ Time Frame: Quarterly ]
  • Serial quarterly lymphocyte measures (ALC, CD4+, CD8+, and CD3+ cell counts, CD4%, CD8%, CD4:CD8) [ Time Frame: Quarterly ]
  • Serial quarterly HIV RNA plasma viral load [ Time Frame: Quarterly ]
  • Serum chemistries: Glucose, BUN, creatinine, total protein, albumin, alkaline phosphatase, ALT, AST, total bilirubin, [ Time Frame: Quarterly ]
  • Serum micronutrient levels: carotene (quarterly), vitamin B12 (quarterly), folate (six monthly) and vitamin D (25-OHD six monthly) [ Time Frame: Quarterly or as specified ]
  • Quality of Life measures [ Time Frame: Quarterly ]

Estimated Enrollment: 218
Study Start Date: January 2009
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: A: Broad spectrum micronutrients
The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week. The intervention will last for two years.
Dietary Supplement: Micronutrients and antioxidants

8 capsules twice daily for two years

Other Name: K-PAX Ultra
Active Comparator: B: Identical appearing multivitamins
The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week. The intervention will last for two years.
Dietary Supplement: Multivitamins and minerals

8 capsules twice daily for two years

Other Name: Centrum-like multivitamins and minerals

Detailed Description:

Background: Antiretroviral therapy (ART) has improved the prognosis of persons with human immunodeficiency virus (HIV) infection, but is expensive and potentially toxic. Micronutrient deficiencies occur even in early stages of HIV infection and increase risk of morbidity, disease progression to acquired immunodeficiency syndrome (AIDS) and mortality, but the role of micronutrient antioxidant supplements in medical management of HIV/AIDS is not clear.
Objective: To determine if supplementation of untreated asymptomatic HIV-infected persons with a broad-spectrum micronutrient and antioxidant preparation will reduce the rate of decline of CD4 T lymphocyte count, or delay emergence of documented CDC-defined AIDS-defining illness, or start of ART compared to 100% recommended daily allowance (RDA) multivitamins and minerals, and is safe.
Study design: A prospective, randomized, controlled, double blind clinical trial of supplementation of 218 untreated asymptomatic HIV-infected adults with a micronutrient and antioxidant preparation or identical appearing RDA multivitamins and minerals for two years, with quarterly follow up in clinic for assessment of time from baseline to CD4 count <350 mm3, or emergence of documented CDC-defined AIDS-defining illness, or start of ART.
Participants and sample size: 218 participants from clinics in Ontario and other participating centres of the CIHR Canadian HIV Trials Network (CTN).
Study duration: approximately five years, allowing for approximately three years for participant accrual and two years follow-up.
Eligibility criteria: The main eligibility criteria are:
• Asymptomatic HIV-infected adults at least 18 years of age
• CD4+ cells ≥375 and ≤750 cells/mm3
• No previous ART (excluding less than seven days and perinatal transmission prophylaxis) Study intervention: Oral supplementation with a broad spectrum micronutrient and antioxidant preparation (n=109) or identical appearing RDA multivitamins and minerals (n=109).
Primary outcome: Time from baseline to CD4+ cell count <350 cells/mm3 (confirmed by two measures at least one week apart), or emergence of documented CDC-defined AIDS-defining illness, or start of ART
Secondary outcomes:
• Non-AIDS related adverse events
• Tolerance of and adherence to study medication
• Time from baseline to CD4+ cell count <350 cells/mm3 (confirmed by two measures at least one week apart)
• Time from baseline to emergence of documented CDC-defined AIDS-defining illness
• Time from baseline to start of ART
• Serial quarterly lymphocyte measures: absolute lymphocyte count (ALC), CD4+, CD8+, and CD3+ cell counts, CD4%, CD8%, CD4:CD8
• Serial quarterly HIV RNA plasma viral load
• Serum chemistries: Glucose, BUN, creatinine, total protein, C-reactive protein, albumin, alkaline phosphatase, ALT, AST, total bilirubin
• Serum micronutrient levels: Carotene (quarterly) and vitamin B12 (quarterly), folate (six monthly) and vitamin D (25-OHD, six monthly)
• Quality of Life measures: MOS HIV, EuroQol, and Health Utilities Index (HUI) Statistical analysis: Analysis of the primary outcome by intention-to-treat will compare time from baseline to primary outcome. Interim analyses are planned once 100 participants are followed for one year.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • be an asymptomatic HIV infected adult
  • at least 18 years of age
  • have CD4+ cells between 375 and 750 cells/mm3
  • have received no ART (excluding less than seven days and perinatal transmission prophylaxis)
  • if a woman of child bearing potential, have a negative pregnancy test within two weeks prior to randomization and agree to practice barrier method of birth control during the study
  • be willing and able to sign informed consent and to comply with the study protocol


Exclusion Criteria:
  • have HIV-2 infection alone
  • have known allergy or intolerance to any study medication ingredient
  • be pregnant
  • have active treatment for an acute opportunistic infection or malignancy
  • have ALT greater than 3 x normal range
  • have known cirrhosis of the liver
  • have serum creatinine less than 133 umol/L
  • abuse alcohol and recreational drugs
  • be taking micronutrient (except vitamin D*) or natural health product supplements
within 30 days of randomization *Maximum 2000 IU daily (Health Canada Guidelines).

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00798772

Locations

Canada
The Ottawa Hospital, General Campus
Ottawa, Ontario, Canada, K1H 8L6

Sponsors and Collaborators

Ottawa Hospital Research Institute
CIHR Canadian HIV Trials Network
Ontario HIV Treatment Network

Investigators

Principal Investigator: William Cameron, MD, FRCPC University of Ottawa at The Ottawa Hospital
More Information

More Information


Responsible Party: Ottawa Hospital Research Institute  
ClinicalTrials.gov Identifier: NCT00798772   History of Changes  
Other Study ID Numbers: CTN 238  
Study First Received: November 25, 2008  
Last Updated: April 3, 2017  
Individual Participant Data    
Plan to Share IPD: Undecided  

Keywords provided by Ottawa Hospital Research Institute:

HIV infection
Micronutrients
Antioxidants

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Antioxidants
Micronutrients
Trace Elements

ClinicalTrials.gov processed this data on December 15, 2017
This information is provided by ClinicalTrials.gov.